

Temporary COVID-19 vaccine rate

In our continued commitment to the state of Arkansas during the ongoing effort to address COVID-19, Summit Community Care is aligning our vaccination policy with Arkansas Medicaid.

On August 11, 2021, Governor Asa Hutchinson announced a temporary increase in the reimbursement rate for the administration of COVID-19 vaccines to begin August 13, 2021, and currently set to expire on October 11, 2021. Summit Community Care will implement the new rate for the duration of the temporary policy.

The increase applies to both first and second vaccination administration of Pfizer and Moderna, or a single shot of the Johnson & Johnson vaccination.

We expect configuration of the rate on or before September 7, 2021. Claims submitted before September 7 for dates of service on or after August 13, 2021, will reprocess at the updated rate by September 21, 2021. Effected codes are listed below.

Please note that there will be a separate notice related to pharmacy point of sale billing.

Procedure code	Description	Manufacturer	Rate
0001A	Immunization administration by intramuscular injection of severe acute respiratory syndrome Coronavirus 2 (SARS-COV-2) (Coronavirus Disease Covid-19) Vaccine, MRNA-LNP, Spike Protein, Preservative Free, 30 MCG/0.3ML dosage, diluent reconstituted; First dose	Vaccine Admin (Pfizer)	\$100
0002A	Immunization administration by intramuscular injection of severe acute respiratory syndrome Coronavirus 2 (SARS-COV-2) (Coronavirus Disease Covid-19) Vaccine, MRNA-LNP, Spike Protein, Preservative Free, 30 MCG/0.3ML dosage, diluent reconstituted; Second dose	Vaccine Admin (Pfizer)	\$100
	Immunization administration by intramuscular injection of severe acute respiratory syndrome Coronavirus 2 (SARS-COV-2) (Coronavirus	Vaccine Admin (Moderna)	

Procedure code	Description	Manufacturer	Rate
0011A	Disease Covid-19) Vaccine, MRNA-LNP, Spike Protein, Preservative Free, 100 MCG/0.5ML dosage; first dose		\$100
0012A	Immunization administration by intramuscular injection of severe acute respiratory syndrome Coronavirus 2 (SARS-COV-2) (Coronavirus Disease Covid-19) Vaccine, MRNA-LNP, Spike Protein, Preservative Free, 100 MCG/0.5ML dosage; second dose	Vaccine Admin (Moderna)	\$100
0031A	Immunization administration by intramuscular injection of severe acute respiratory syndrome Coronavirus 2 (SARS-COV-2) (Coronavirus Disease Covid-19) Vaccine, MRNA-LNP, Spike Protein, Preservative Free, 5x10 ¹⁰ viral particles/0.5ML dosage, Single dose	Vaccine Medication (Johnson & Johnson)	\$100
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) (Coronavirus Disease Covid-19) Vaccine, MRNA-LNP, Spike Protein, Preservative Free, 30 MCG/0.3ML Dosage, Diluent Reconstituted, for intramuscular use	Vaccine Medication (Pfizer)	\$0.01
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) (Coronavirus Disease Covid-19) Vaccine, MRNA-LNP, Spike Protein, Preservative Free, 100 MCG/0.5ML dosage, for intramuscular use	Vaccine Medication (Moderna)	\$0.01
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) (Coronavirus Disease Covid-19) Vaccine, MRNA-LNP, Spike Protein, adenovirus type 26 (AD26) vector, preservative free, 5x10 ¹⁰ viral particles/0.5ML dosage, for intramuscular use	Vaccine Medication (Johnson & Johnson)	\$0.01

If you have questions about this communication or need assistance with any other item, contact your local Provider Relations representative or call Provider Services at **844-462-0022**.